NCT07535567: Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma
- State
- Not started
- Phase
- Phase 2 and Phase 3
- People
- 386 planned
- Started
- 5 May 2026
- Primary completion
- 31 Dec 2028
- Arms
- IMRT-Nimotuzumab + Benmelstobart
- Results
- None posted
- 17 Apr 2026: Trial registered